356 related articles for article (PubMed ID: 24091594)
1. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
Hadji P; Felsenberg D; Amling M; Hofbauer LC; Kandenwein JA; Kurth A
Osteoporos Int; 2014 Jan; 25(1):339-47. PubMed ID: 24091594
[TBL] [Abstract][Full Text] [Related]
2. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study.
Cooper A; Drake J; Brankin E;
Int J Clin Pract; 2006 Aug; 60(8):896-905. PubMed ID: 16800837
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
Paggiosi MA; Peel N; McCloskey E; Walsh JS; Eastell R
Osteoporos Int; 2014 Dec; 25(12):2729-41. PubMed ID: 25074351
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
5. Comparative adherence to weekly oral and quarterly intravenous bisphosphonates among patients with limited heath literacy who sustained distal radius fractures.
Roh YH; Noh JH; Gong HS; Baek GH
J Bone Miner Metab; 2018 Sep; 36(5):589-595. PubMed ID: 28983705
[TBL] [Abstract][Full Text] [Related]
6. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
Petranova T; Boyanov M; Shinkov A; Petkova R; Intorcia M; Psachoulia E
Arch Osteoporos; 2017 Dec; 13(1):1. PubMed ID: 29264666
[TBL] [Abstract][Full Text] [Related]
7. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials.
Lee YH; Song GG
Korean J Intern Med; 2011 Sep; 26(3):340-7. PubMed ID: 22016595
[TBL] [Abstract][Full Text] [Related]
9. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate.
Kendler DL; McClung MR; Freemantle N; Lillestol M; Moffett AH; Borenstein J; Satram-Hoang S; Yang YC; Kaur P; Macarios D; Siddhanti S;
Osteoporos Int; 2011 Jun; 22(6):1725-35. PubMed ID: 20827547
[TBL] [Abstract][Full Text] [Related]
10. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
Freemantle N; Satram-Hoang S; Tang ET; Kaur P; Macarios D; Siddhanti S; Borenstein J; Kendler DL;
Osteoporos Int; 2012 Jan; 23(1):317-26. PubMed ID: 21927922
[TBL] [Abstract][Full Text] [Related]
11. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
[TBL] [Abstract][Full Text] [Related]
12. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
Rossini M; Viapiana O; Gatti D; Adami S
Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
[TBL] [Abstract][Full Text] [Related]
13. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
Miller PD; Epstein S; Sedarati F; Reginster JY
Curr Med Res Opin; 2008 Jan; 24(1):207-13. PubMed ID: 18042311
[TBL] [Abstract][Full Text] [Related]
14. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis.
Cotté FE; Fardellone P; Mercier F; Gaudin AF; Roux C
Osteoporos Int; 2010 Jan; 21(1):145-55. PubMed ID: 19459025
[TBL] [Abstract][Full Text] [Related]
15. Ibandronate: a review of its use in the management of postmenopausal osteoporosis.
Frampton JE; Perry CM
Drugs; 2008; 68(18):2683-707. PubMed ID: 19093707
[TBL] [Abstract][Full Text] [Related]
16. Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass.
Hadji P; Gamerdinger D; Spieler W; Kann PH; Loeffler H; Articus K; Möricke R; Ziller V
Osteoporos Int; 2012 Feb; 23(2):625-33. PubMed ID: 21442459
[TBL] [Abstract][Full Text] [Related]
17. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
[TBL] [Abstract][Full Text] [Related]
18. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
Naylor KE; Jacques RM; Paggiosi M; Gossiel F; Peel NF; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2016 Jan; 27(1):21-31. PubMed ID: 25990354
[TBL] [Abstract][Full Text] [Related]
19. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
Reginster JY
Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506
[TBL] [Abstract][Full Text] [Related]
20. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
Hadji P; Claus V; Ziller V; Intorcia M; Kostev K; Steinle T
Osteoporos Int; 2012 Jan; 23(1):223-31. PubMed ID: 21308365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]